Psychedelic Nasal Spray for Depression: What the Research Shows

What Is BPL-003 and Why Is It Getting Attention?

Most conversations about psychedelic medicine focus on psilocybin or ketamine. A newer compound is now drawing serious scientific attention: BPL-003, an intranasal formulation of mebufotenin benzoate, which is a stabilized salt form of 5-MeO-DMT. Developed by Beckley Psytech and atai Life Sciences (now merged as AtaiBeckley), it is designed to be administered as a psychedelic nasal spray for depression in a clinical or supervised outpatient setting.

The compound works by delivering 5-MeO-DMT directly through the nasal passage, producing rapid absorption and a short but intense psychedelic experience. Unlike psilocybin sessions that can last four to six hours, BPL-003 produces its primary effects in a much shorter window, which is clinically significant for anyone thinking about how this fits into real-world treatment settings.

What the Clinical Evidence Actually Shows

The research behind BPL-003 is at an early but compelling stage. Here is what we know so far.

A Phase 2b randomized trial involving 193 participants with treatment-resistant depression found that both the 8 mg and 12 mg doses produced statistically significant reductions in depression scores, as measured by the Montgomery-Asberg Depression Rating Scale (MADRS), as early as day two after a single administration. The 8 mg dose showed a mean 12.1-point reduction from baseline at day 29, compared to a 5.8-point reduction in the active control group. The 12 mg dose produced an 11.1-point reduction. Crucially, effects were sustained over at least eight weeks in many participants.

A separate open-label Phase 2a study published in the Journal of Psychopharmacology in February 2026 followed 12 patients with moderate-to-severe treatment-resistant depression who received a single 10 mg dose. The mean MADRS score dropped by 12.6 points by day two and remained reduced across a 12-week observation period. Ten of the twelve participants met discharge readiness criteria within 90 minutes of dosing, and the majority were considered clinical responders at one or more follow-up points.

In October 2025, the FDA granted BPL-003 Breakthrough Therapy designation, a status reserved for drugs addressing serious conditions where early evidence suggests meaningful improvement over existing therapies. Phase 3 trials are expected to begin in the second quarter of 2026.

This is where things get more nuanced. These are still early-stage results. Most participants in these trials received psychological support alongside the dosing session. The data is promising, but it is not a finished story.

How Does It Differ from What Already Exists?

The closest approved comparison is esketamine (Spravato), an FDA-approved nasal spray for treatment-resistant depression derived from ketamine. BPL-003 belongs to a different pharmacological class entirely. Where esketamine primarily blocks NMDA receptors, 5-MeO-DMT acts on serotonin receptors and produces a qualitatively different experience, including, in many participants, what researchers describe using the Mystical Experience Questionnaire as a “complete mystical experience.”

The practical implication is that BPL-003 sits closer to classical psychedelic-assisted therapy in character, even if its duration is far shorter. That short duration is actually one of its clinical advantages: participants in the Phase 2b trial were generally ready for discharge within two hours, which aligns with outpatient treatment workflows and lowers the logistical barrier compared to longer-acting substances.

This also means the preparation and integration question becomes more acute, not less. A two-hour clinical window can still produce a significant perceptual and emotional shift. What a person does with that shift in the days and weeks that follow is not a secondary concern.

Why Integration Is Not Optional

Clinical trials measure symptom reduction at defined intervals. They are not designed to answer the question of what makes those reductions last, and the gap between a statistically significant MADRS score reduction and a person living better six months later is wide enough to matter. That is where the clinical data ends and the real-world experience begins.

People who experience rapid symptom relief from a psychedelic intervention often describe it as a window opening, a brief period of clarity or reduced psychological rigidity in which new perspectives feel more accessible. What happens in that window matters enormously. Without structure to support it, old patterns, stress responses, and unresolved emotional material have a way of reasserting themselves.

At JourneyŌM, integration is the core of what we offer. Our guides work with seekers before an experience to establish intention and context, and after the session to help process what emerged and translate insights into sustainable change. This is not supplementary care. It is where the actual work happens.

Integration support looks different for each person. For some it means structured check-ins over several weeks. For others it includes practices like reflective journaling, breathwork, or somatic work to help the nervous system settle into new patterns. The goal is not to relive the experience but to carry what was useful forward into daily life.

What This Means for Seekers Right Now

BPL-003 is not available outside of clinical trials as of early 2026, and Phase 3 trials are still in preparation. If you are struggling with treatment-resistant depression and are curious about this class of treatment, here is what is worth knowing.

First, the landscape of legally accessible psychedelic-assisted options is broader than most people realize. Ketamine therapy is available through licensed providers in most US states. Psilocybin services are legal in Oregon and Colorado. These are not identical to BPL-003, but they involve similar principles around preparation, set and setting, and integration support.

Second, the preparation you do before any psychedelic experience and the integration work you do afterward are not add-ons. The clinical literature, across multiple substances and study designs, consistently points to psychological support as a key variable in outcomes. Choosing to engage with this work thoughtfully, with a vetted guide, is one of the most meaningful decisions a seeker can make.

Third, anyone considering a psychedelic experience for depression should be working with a qualified healthcare provider to assess appropriateness, screen for contraindications, and coordinate with any existing treatment. This is not a self-directed process.

Where the Research Is Heading

AtaiBeckley is advancing BPL-003 into a pivotal Phase 3 program, with initiation expected in Q2 2026 following a successful End-of-Phase 2 meeting with the FDA. A separate Phase 2a cohort is evaluating a two-dose induction regimen of 8 mg followed by 8 mg, with initial data expected in late 2026. Researchers are also investigating BPL-003 for alcohol use disorder, expanding its potential therapeutic scope.

The trajectory is meaningful. Breakthrough Therapy designation, peer-reviewed publication in the Journal of Psychopharmacology, and sustained MADRS score reductions across multiple study designs all point to a compound worth watching carefully. But the researchers themselves are measured in how they describe what is still unknown. Dosing optimization, long-term safety, and the precise role of psychological support are all active questions.

We think that measured tone is the right one. This is a genuinely promising area of research. It is not a breakthrough that has arrived yet, and the people most likely to benefit from it are those who engage with it with that understanding in place.